

Treatment of Locally Advanced Pancreatic Cancer

Does Neoadjuvant Chemoradiation Downstage Locally Advanced Pancreatic Cancer? Memorial Sloan-Kettering Cancer Center

- Patients admitted between January 1993 and March 1999 with locally advanced pancreatic AC were identified (N=163)
- Chemoradiation was administered to 87 (53.3%) of 163, and regimens varied from standard 5-fluorouracil/ gemcitabine–based therapies to experimental protocols

Clinical Response

- Clinical response:
- PR > 50% 3/87 (3.4%)
- Exploration 1/3 operable
- The overall median survival for all patients with locally advanced disease treated with
- chemoradiation was 11 months vs. 6 m for other modalities ($p > .004$).

Hong Jin Kim et al (J GASTROINTEST. SURG. 2002;6:763–769.)

© 2002

Median OSR after pancreatectomy alone

Trial	n	FU (m)	MOS	Act. S
GITSG,87	22	11	11	15% (2y)
Bakkevold, 93	31	NA	11.4	8% (5y)
EORTC,93	54	NA	12.6	10% (5y)
ESPACE,04	69	47	16.9	11% (5y)

Rationale of preoperative CRT

- Multimodality therapy may be of benefit
- Estimated 30% of patients escape PO adjuvant treatment
- High incidence of positive SM
- To improve patient selection to surgery

PO CRT in pancreatic cancer

Trial	n	MOS	P value
GITSG,85 S	21 22	20 21	.03
EORTC,93 S	60 54	17.1 12.6	.099
ESPAC,03	176 178	15.5 16.5	.24